Member Info for chromeinvestor

Bojo has set aside £100bn for TTT. We only need a small percent of this to be transformational

As I said earlier, NCYT staff are going flat out, but they cant perform miracles. Scaling up any business takes time. The speed NCYT has grown is unprecedented.

I'm not really interested in anything under £15. At that time, I will review sales figures/news and re-assess

I already have-looking like an opportune purchase. That's why I never complain about these games-just take advantage of them

Absolutely-Just topped up

I'm expecting a TR1 to show up any day-All of these late buys showing can only mean someone is stakebuilding

This would not be stopping at the £6/7 or £8 station :)

Looking good for a sustained breakout from here

It was qiagen

Are we part of the rapid test at Southampton hospital?
BBC have an article on it

This stock is hard to value as we dont know how long the covid tests will be required for. At some time in the future the orders may cease completely. That;s why you cannot value it like a normal share

I've maxed out here-time to sit back and let the fundamentals do the talking

Suggest all investors take another read of the latest results-All the clues are there-this company has exciting plans and it's not all dependent on Covid products-that's just the springboard!

Superb foresight and planning from NCYT management team

From the results:
Launch of three new innovative products (Exsig™ Direct, Exsig™ Mag and COVID-HT) to support laboratories through improving workflow efficiency and helping to address the reported shortfall in global manufacturing and supply of extraction reagents
This included increasing the Company's own production capacity at the Primerdesign site in Southampton, UK, as well as entering into contract manufacturing partnerships. The Company also needed to manage suppy chain capacity, which included expanding its key raw material supplier base to develop a long-term and sustainable high volume supply of its tests.
nventory has increased by €13.2m to €15.6m from €2.4m at 31 December 2019. The majority of the inventory balance relates to building stock to meet the needs of the COVID-19 pandemic and allow Novacyt to fulfil customer demand immediately. The lead time for obtaining some raw materials is significant, so bulk orders have been placed to ensure there are no supply chain issues, which resulted in the higher raw materials balance at 30 June 2020.

Did NCYT not forward purchase stock of the required reagent?

I believe we have just started the process here. Onwards and upwards!

Copy their name, click on "filters" tab just above the posts (three grey tabs). Paste name in and add to filter list-Long winded (typical of LSE)

Did I miss the party?

The real action is taking place quietly-the large buys are mostly being reported late. Someone is accumulating whilst trying to keep a lid on the sp (AIMHO)